AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca plc (LON: AZN) confirmed on Tuesday that it had sold commercial rights to its drug for hypertension management for £294.44 million to Cheplapharm Arzneimittel GmbH. AstraZeneca is almost flat on average on the intraday chart.

AstraZeneca completes sale of commercial rights to Atacand for £294 million

Moderna

Pfizer

Tesla

Tech Finishes as the Strongest Sector in 2020

Prime Minister Boris Johnson announced a “very difficult” period ahead as the second wave of the pandemic shows no sign of receding.

AstraZeneca Vaccine Rolled Out in U.K. as Country Heads Toward Tougher Restrictions

The UK is the first country in the world to give people the COVID-19 vaccine developed by Oxford University and AstraZeneca outside of a trial. There are 530,000 doses ready to give to people on Monday, and "tens of millions" will be available by March 31 according to the Department of Health. The UK government has secured 100 million doses overall.  The six hospital trusts to get the vaccine initially are in London, Sussex, Lancashire and Warwickshire. Eighty three year-old dialysis patient Brian Pinker was the first person to receive his shot in Oxford.  The Oxford professor who pioneered the vaccine, Andrew Pollard, has also been immunized.

UK government says it will give 'tens of millions' AstraZeneca-Oxford COVID-19 vaccine doses by end of March — here's how.

An 82-year-old dialysis patient has become the first person to receive the AstraZeneca–Oxford COVID-19 vaccine.

First country rolls out AstraZeneca-Oxford vaccine as EU faces challenges with its inoculations.

The U.K. is the first country in the world to approve and use the vaccine for emergency use.

‘A Pivotal Moment': U.K. Rolls Out Oxford-AstraZeneca Vaccine Amid Covid-19 Surge

The U.K. greenlighted AstraZeneca's vaccine, but don't take that as a signal to buy. AZN stock looks terrible.

Vaccine News May Make AstraZeneca Stock Seem Worth a Shot, But It's Not

The U.K. is to start rolling out the coronavirus vaccine developed by AstraZeneca and the University of Oxford on Monday.

UK rolls out Oxford-AstraZeneca vaccine as it battles against Covid surge

The massive country gives AZD1222 the nod for emergency use, in addition to a vaccine from local company Bharat Biotech.

AstraZeneca and University of Oxford's Coronavirus Vaccine Approved in India

Health officials in India on Sunday approved two COVID-19 vaccines, including one made by AstraZeneca, for emergency use.  "A decisive turning point to strengthen a spirited fight," India's prime minister, Narendra Modi, said on Twitter.

AstraZeneca's COVID-19 vaccine has been approved for emergency use in India, along with a local drugmaker's alternative shot

Some 300 million people in India are set to get the vaccine made by AstraZeneca and Oxford University. What Happened: India, which has a population of 1.35 billion people, has approved its first COVID-19 vaccine and has three more in the works.

India Approves Its First Emergency-Use COVID-19 Vaccine

It's a great pharmaceutical company right now, but probably not for the reasons you think.

4 Reasons to Buy AstraZeneca Stock Now

Drugmaker AstraZeneca has reportedly vowed to increase its production to 2 million shots per week by mid-January, even as government vaccine rollouts fall short of expectations.  "The plan is then to build it up fairly rapidly – by the third week of January we should get to two million a week," an unnamed AstraZeneca staffer told The Times.

AstraZeneca says it is increasing COVID-19 vaccine production to 2 million a week, as government rollouts miss their targets

AstraZeneca's (AZN) vaccine for coronavirus receives emergency use approval in the United Kingdom, the first for it anywhere in the world.

AstraZeneca (AZN) COVID-19 Vaccine Gets Authorization in UK

Johnson & Johnson

If you can afford to invest the money, these stocks could help you make the most of it.

3 Stocks That Could Double Your $600 Stimulus Check

AstraZeneca stock rose slightly Wednesday after U.K. officials authorized its University of Oxford-partnered coronavirus vaccine for emergency use in people ages 18 and older. The post AstraZeneca Wins U.K. Authorization For Covid Vaccine; Shares Edge Higher appeared first on Investor's Business Daily.

AstraZeneca Wins U.K. Authorization For Covid Vaccine; Shares Edge Higher

The two announcements provide a welcome shot in the arm for global health efforts amid reports of a new mutation of the coronavirus. Despite a slow start to U.S. vaccinations, there was good news abroad this week as the United Kingdom gave emergency-use authorization to the COVID-19 vaccine produced by AstraZeneca and the University of Oxford.

COVID-19 update: Chinese vaccine maker claims 79% efficacy as U.K. approves AstraZeneca

The first authorization of its vaccine could be the only green light it receives for several months.

The U.K. Authorizes AstraZeneca's Coronavirus Vaccine for Emergency Supply

The latest vaccine to be approved is cheaper and easier to store, and comes as Covid-19 infections and hospitalizations are spiking in Britain due largely to a new variant of the virus.

U.K. Approves AstraZeneca-Oxford Covid-19 Vaccine, With First Doses Being Rolled Out Next Week

AZN's COVID-19 vaccine received emergency use authorization in the U.K. AZN's Q3 revenue grew at 3% and EBITDA grew in the double-digit percentage range on cost-containment efforts.

AstraZeneca's COVID-19 Vaccine Could Be A Shot In The Arm

The United Kingdom on Wednesday become the first country to approve the coronavirus vaccine developed by Oxford University and AstraZeneca. The shot is cheaper and easier to distribute than alternatives, and is expected to play a crucial role in boosting the global economy next year.

Why the AstraZeneca vaccine is so important to the global economy

AstraZeneca's stock jumped on Wednesday after Britain authorized emergency use of the COVID-19 vaccine it developed with Oxford University.  The pharma group was among the FTSE 100's leaders as its shares jumped 0.7% in early European trading. Its shares were up about 3.3% at the start of trade.

AstraZeneca's stock jumps after the UK authorizes emergency use of its vaccine, which it created with Oxford University

Oxford Biomedica notes AstraZeneca's COVID-19 vaccine has been authorised for emergency supply in the UK

AstraZeneca plc (LON: AZN) said it received approval from the United Kingdom for its COVID-19 vaccine that it developed in collaboration with Oxford University on Wednesday. Britain is the 1st country to have approved the pharmaceutical giant's COVID-19 vaccine for use as it struggles to combat the pandemic that has so far infected more than 2.3 million people countrywide and caused over 71 thousand deaths.

Britain becomes the first country to approve AstraZeneca's COVID-19 vaccine

The Oxford University/AstraZeneca vaccinations will begin in early 2021.

News for AstraZeneca Stock (AZN)